Angiotensin receptor blockers for the treatment of covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trial.

ABSTRACT:

Objective

To determine whether disrupting the renin angiotensin system with angiotensin receptor blockers will improve clinical outcomes in people with covid-19.

Design

CLARITY was a pragmatic, adaptive, multicentre, phase 3, randomised controlled trial.

Setting

17 hospital sites in India and Australia.

Participants

Participants were at least 18 years old, previously untreated with angiotensin receptor blockers, with a laboratory confirmed diagnosis of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection who had been admitted to hospital for management of covid-19.

Intervention

Oral angiotensin receptor blockers (telmisartan in India) or placebo (1:1) for 28 days.

Main outcome measures

The primary endpoint was covid-19 disease se

SUBMITTER: Jardine MJ 

PROVIDER: S-EPMC9667467 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature